ACUTE TOXICITY TESTING OF DBL beta 2 PFEMP1 RECOMBINANT PROTEIN AS A CANDIDATE FOR MALARIE VACCINE BASED ON PEPTIDE leny Yulia widia sari (a), Erma Sulistyaningsih(b), Tri Agus Siswoyo(b)
a) Mahasiswa Universitas Jember
Jl. Kalimantan Tegalboto No.37, Krajan Timur, Sumbersari, Kec. Sumbersari, Kabupaten Jember, Jawa Timur 68121
b) Universitas Jember
Jl. Kalimantan Tegalboto No.37, Krajan Timur, Sumbersari, Kec. Sumbersari, Kabupaten Jember, Jawa Timur 68121
Abstract
Malaria is an infectious disease caused by plasmodium. The pathogenic mechanism responsible for severe malaria symptoms in Plasmodium falciparum infection is the adhesion of infected erythrocytes (IE) to the microvasculature in vital organs, resulting in organ failure and death, which is mediated by P. falciparum erythrocyte membrane protein 1 (PfEMP1). It is a complex protein, the head structure of PfEMP1 consist of Duffy binding-like (DBL) domain (alfa,beta,gama,delta) and cysteine-rich interdomain region (CIDR) domain (alfa, beta, gamma, delta). The DBL beta2 PfEMP1 domain toxicity test was conducted to obtain information as the basis for the development of peptide-based vaccines.Observation of the toxicity test was carried out by injecting the peptide at a dose of 750 ug in male and female rats. The results of the study during 14 days of observation that there was no weight loss and weight gain of rats, rats did not show any toxic symptoms. The results of IL 6 and TNF alfa examination with ELISA showed no statistically significant difference between the control group and the treatment group. This study shows that the DBL beta2 PfEMP1 recombinant protein from P.falciparum is not toxic so it can be used as a candidate for peptide-based malaria vaccine.
Keywords: Malaria, DBL beta2 PfEMP1 recombinant protein, Acute toxicity test
